VEGF-B Inhibition Prevents And Treats Diabetes

By using a new approach while experimenting on mice and rats, scientists have managed to both prevent the development of type II diabetes and reverse the progression of established disease.

The therapy involves the blockade of signalling by a protein known as VEGF-B and this prevents fat from accumulating in the 'wrong' places, such as in muscles and in the heart. As a result the cells within these tissues are once again able to respond to insulin.

Diabetic Diet - Diabetes Mellitus
The diabetic diet most often recommended is high in dietary fiber (especially soluble fiber) and nutrients, but low in fat (especially saturated fat) and moderate in calories.

The findings, which have been described as a breakthrough in diabetes research, are the result of a joint effort by Karolinska Institutet, the Ludwig Institute for Cancer Research and the Australian biopharmaceutical company CSL Limited, amongst others.

"It's a great feeling to present these results," said Professor Ulf Eriksson of the Department of Medical Biochemistry and Biophysics at Karolinska Institutet.

"We discovered VEGF-B back in 1995, and since then the VEGF-B project has been a lengthy sojourn in the wilderness, but now we're making one important discovery after the other. In this present study we've shown that VEGF-B inhibition can be used to prevent and treat type II diabetes, and that this can be done with a drug candidate," Prof Eriksson stated.

Gestational Diabetes About
The condition is not caused by a lack of insulin, but by the action of hormones produced during pregnancy that blocks the action of insulin.

Type II diabetes is normally preceded by insulin resistance caused by obesity. When this happens, the cells no longer respond sufficiently to insulin, which leads to elevated levels of blood sugar. Insulin resistance is related to the storage of fat in the 'wrong' places, such as the muscles, blood vessels and heart, although exactly how this relationship works is not fully known.

What scientists do know, however, is that the VEGF-B protein affects the transport and storage of fat in body tissue. This was discovered by Professor Ulf Eriksson's research group in a study published in Nature in 2010.

Screening for Diabetes - Test - Frequently Asked Questions
Diabetes screening is done using blood tests like fasting blood sugar and hemoglobin A1c levels. Diabetes affects 8.3% Americans and about 10% Indians.

These theories have now been developed for a new study in which VEGF-B signalling was blocked in a group of diabetic mice and rats.

In one study, mice bred to spontaneously develop diabetes were given a drug candidate called 2H10, which is an antibody that blocks the effect of VEGF-B. The mice subsequently developed neither insulin resistance, nor diabetes. The team also crossed the diabetes strain of mice with one that lacked the ability to produce VEGF-B, and found that the offspring were protected from developing the disease.

Changes in Gut Bacteria may Cause Diabetes
Diabetes may be caused by harmful pathogens present in the gut, say researchers.

In another two studies, the scientists took normal mice and rats that had not been specially bread to develop type II diabetes, and left them to develop the disease as a result of a fat-rich diet and the resulting obesity. In these cases, progression of the established disease was halted and reversed to varying degrees after treatment with 2H10.

"The results we present in this study represent a major breakthrough and an entirely new principle for the prevention and treatment of type II diabetes," said Professor Ake Sjoholm, consultant in diabetology at Stockholm South General Hospital.

The drug candidate used in the study, 2H10, is a monoclonal antibody and is being developed by the biopharmaceutical company CSL Limited.

The study has been published in the prestigious scientific journal Nature.

Source-ANI